S. Herschorn, J. Nazir, B. Ramos, and Z. Hakimi, “Supplementary data: Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada”, CUAJ, vol. 11, no. 3-4, pp. E129–33, Apr. 2017.